J&J booster confusion ahead

Data collected by the National Institutes of Health show that people who received a shot of Johnson & Johnson’s coronavirus vaccine have a stronger neutralizing antibody response if they receive an mRNA shot instead of a second J&J one, according to a person who has seen the data.

Yes, but: J&J has asked the FDA to authorize a second shot of its own vaccine, which could make any attempt to authorize mix-and-matching vaccines confusing for the public.

State of play: An FDA advisory panel is considering booster shots for J&J recipients and some recipients of the Moderna vaccine this week.

On Friday, when the panel will focus on J&J, the NIH will present findings from its mix-and-match booster study, according to the draft agenda of the meeting. That data is expected to show a significantly stronger neutralizing antibody response — which is a form of immune protection — to an mRNA booster than to a second dose of J&J.But J&J hasn’t asked the FDA to authorize mixing and matching its vaccine with another one, which could make the process messy. It’s unclear how a mix-and-match authorization process would play out.

But, but, but: There are limitations to the NIH data. Neutralizing antibodies are only one form of immune protection, and it’s unclear how long the response will last.

The bottom line: The most interesting part of Friday’s meeting may be how the panel addresses the questions that aren’t being asked by J&J — but are of significant interest to the 15 million Americans who received their shot.

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on print
Share on email
Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on print
Share on email